[1] Alam MM,Mahtab MA,Akbar SM,et al. Hepatic necroinflammation and severe liver fibrosis in patients with chronic hepatitis B with undetectable HBV DNA and persistently normal alanine aminotransferase. Bangladesh Med Res Counc Bull,2014,40:92-96.
[2] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版). 肝脏,2015,20: 915-932.
[3] 龙琴,白浪,杜凌遥,等.慢性乙型肝炎肝硬化患者使用核苷(酸)类似物抗病毒抗纤维化的临床疗效.肝脏,2016,21:279-282.
[4] 陈育霞,李东良.抗病毒治疗对慢性乙型肝炎患者肝脏组织学的影响.肝脏,2016,21:823-826.
[5] 于高平,宋春霞,刁力,等.恩替卡韦治疗慢性乙型肝炎临床疗效评价.肝脏,2014,19:384-386.
[6] 丁岗强,康谊,刘俊平,等. 乙肝病毒耐药导致慢性重型肝炎的抗病毒治疗临床疗效分析.中国医学创新,2014,11:6-8.
[7] 丁晋彪,李跃旗,周越,等.恩替卡韦分散片治疗慢性乙型肝炎临床研究.传染病信息,2010,23,:168-171.
[8] 罗东凤,丁南. 恩替卡韦治疗代偿期和失代偿期乙肝肝硬化疗效比较.海南医学,2015,26:3474-3477.
[9] 周建芳,刘芳娟,杨珊明,等. 220 例社区慢乙肝患者抗病毒治疗调查分析.医学信息,2015,28:86.
[10] 高勇,罗秋红,施光亚,等. CTP B级乙肝肝硬化失代偿期26例患者抗病毒治疗长期随访观察.福建医药杂志,2015,37:4-6.
[11] Ahn SH,Chun JY,Shin SK,et al. Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. Clin Mol Hepatol,2013,19:399-408. |
